Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Stockholders Equity of -$119.15 million for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$119.15M | +75.0% |
| 2024 | -$475.93M | -4.5% |
| 2023 | -$455.53M | -54.6% |
| 2022 | -$294.60M | -175.4% |
| 2021 | -$106.99M | -455.4% |
| 2020 | -$19.26M | -150.4% |
| 2019 | $38.25M | -22.3% |
| 2018 | $49.23M | -41.2% |
| 2017 | $83.77M | +5208.4% |
| 2016 | $1.58M | -96.7% |
| 2015 | $47.72M | -36.9% |
| 2014 | $75.64M | +6817.1% |
| 2013 | -$1.13M | -148.0% |
| 2012 | -$454.0K | -103.1% |
| 2011 | $14.81M | -77.4% |
| 2010 | $65.50M | -24.1% |
| 2009 | $86.27M | +85.8% |
| 2008 | $46.43M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$387.89M | +17.2% | +8.0% |
| June 30, 2025 | -$421.59M | +11.4% | +6.7% |
| March 31, 2025 | -$451.93M | +5.1% | +5.0% |
| December 31, 2024 | -$475.93M | -4.5% | -1.6% |
| September 30, 2024 | -$468.56M | -14.0% | +1.5% |
| June 30, 2024 | -$475.61M | -22.4% | +0.1% |
| March 31, 2024 | -$476.17M | -45.0% | -4.5% |
| December 31, 2023 | -$455.53M | -54.6% | -10.8% |
- BIOCRYST PHARMACEUTICALS INC showed an increase of +75.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, BIOCRYST PHARMACEUTICALS INC’s stockholders equity has declined by 356.6% (from $46.43 million to -$119.15 million).
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: